Capabilities by Region: Continental Europe
Greenhill has considerable advisory experience in Continental Europe. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout Continental Europe. Greenhill established its presence in Continental Europe in November 2000 with the opening of a Frankfurt office. Greenhill further expanded its presence with the opening of a Madrid office in 2017 and a Paris office in 2020.
For more information on Greenhill’s advisory practice in Continental Europe and our capabilities in the region, please contact President David Wyles in our London office, Managing Director Philip Meyer Horn in our Frankfurt office, Javier Gonzalez in our Madrid Office or Amélie Négrier-Oyarzabal in our Paris office.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By
Bank of America Corporation
Advised AXA Private Equity, a leading European diversified private equity firm, on the acquisition of a portfolio of limited partnership interests in private equity funds from Bank of America
Verivox Holding Limited
Advised the shareholders of Verivox Holdings Limited, comprising Independent News & Media plc and the founders and joint CEOs of Verivox, on the sale of 51% in Verivox, Germany’s leading price comparison website for energy and telecommunications services, to Oakley Capital Private Equity
Enzon Pharmaceuticals, Inc.
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
PARIS RE Holdings Ltd.
Advised PartnerRe Ltd., a leading global reinsurer, providing multi-line reinsurance to insurance companies, on its acquisition of PARIS RE Holdings Ltd., a French-listed, Swiss-based diversified reinsurer
Genentech, Inc.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company